NCT04899219View on ClinicalTrials.gov

A Study to Investigate the Pharmacokinetics of ACT-1014-6470 in Subjects With Severe Renal Impairment Compared to Control Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 16, 2021

Primary Completion Date

November 12, 2021

Study Completion Date

November 12, 2021

Conditions
Healthy
Interventions
DRUG

ACT-1014-6470 40 mg

ACT-1014-6470 will be available as soft gelatin capsules for oral administration formulated at a dose strength of 20 mg.

Trial Locations (1)

81241

APEX GmbH, Munich

Sponsors
All Listed Sponsors
lead

Idorsia Pharmaceuticals Ltd.

INDUSTRY

NCT04899219 - A Study to Investigate the Pharmacokinetics of ACT-1014-6470 in Subjects With Severe Renal Impairment Compared to Control Subjects | Biotech Hunter | Biotech Hunter